RECURRENT MULTIPLE MYELOMA

This early-stage study is testing the safety and best dose of a new two-drug combination for multiple myeloma that has come back or stopped responding to other treatments. The trial combines an oral pill (iberdomide) that targets cancer cell proteins with an injected immunotherap…

This early-stage trial is testing whether combining three existing drugs—elotuzumab, CC-92480, and dexamethasone—is safe and effective for people with multiple myeloma that has returned or stopped responding to treatment. The study involves 27 patients whose cancer has progressed…

This early-stage trial is testing a new treatment for multiple myeloma that has returned or stopped responding to standard therapies. Doctors will collect patients' own immune cells, use CRISPR gene-editing technology to reprogram them to attack cancer, then infuse them back into…

This study is testing whether adding a new drug called iberdomide to an existing treatment (belantamab mafodotin and dexamethasone) is safe and more effective for people with multiple myeloma that has returned or stopped responding to other therapies. The trial will first find th…

This study is testing a new combination of four medications for people whose multiple myeloma has come back after prior treatment. The first goal is to find a safe dose, and the second is to see how well the combination works at controlling the cancer. It combines an experimental…

This study is testing whether adding two drugs, dasatinib and quercetin, to a powerful cell therapy (CAR-T) can better treat multiple myeloma that has come back or stopped responding to other treatments. The goal is to see if this combination helps the CAR-T therapy work more eff…

This study is testing if different doses and timing of the drug belantamab mafodotin can work better for people with multiple myeloma that has come back or stopped responding to other treatments. The drug is designed to target and kill myeloma cells. Researchers want to see if th…

This study is testing whether doctors can safely lower the dose and frequency of a cancer drug called linvoseltamab for patients with multiple myeloma that has returned or stopped responding to other treatments. The goal is to see if less medicine can still control the cancer whi…

This study is testing a combination of three drugs—mezigdomide, carfilzomib, and dexamethasone—to see if it can control multiple myeloma that has come back or stopped responding to other treatments and has spread to form tumors in soft tissues or organs. It will involve about 28 …

This study is testing whether a personalized exercise program in the weeks before CAR-T cell therapy can help older adults with recurrent multiple myeloma. Researchers want to see if this 'prehabilitation' improves patients' physical strength, fitness, and quality of life both be…